Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Indra Purevjal"'
Autor:
Árpád Illés, Andres Forero-Torres, Sergey Alekseev, Anas Younes, Valeria Buccheri, Keenan Fenton, Pier Luigi Zinzani, Joseph M. Connors, Anna Sureda, Andrea Gallamini, Rachael Liu, Lena Specht, Jan Walewski, Ashish Gautam, Andrew Grigg, Tae Min Kim, Graham P. Collins, Indra Purevjal, David J. Straus
Publikováno v:
Straus, D, Collins, G, Walewski, J, Zinzani, P L, Grigg, A, Sureda, A, Illes, A, Kim, T M, Alekseev, S, Specht, L, Buccheri, V, Younes, A, Connors, J, Forero-Torres, A, Fenton, K, Gautam, A, Purevjal, I, Liu, R & Gallamini, A 2020, ' Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy ', Leukemia and Lymphoma, vol. 61, no. 12, pp. 2931-2938 . https://doi.org/10.1080/10428194.2020.1791846
We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHEL
Autor:
Michael Pecsok, Patrick J. Stiff, Jerzy Holowiecki, Naomi N. H. Hunder, Auayporn Nademanee, Anna Sureda, Indra Purevjal, John W. Sweetenham, Muneer H. Abidi, Mayur Uttarwar
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 24(11)
The phase III AETHERA trial demonstrated the efficacy of brentuximab vedotin (BV) as consolidation therapy in patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression after autologous hematopoietic stem cell transplantatio
Autor:
Jan Walewski, Indra Purevjal, Pier Luigi Zinzani, Valeria Buccheri, Lena Specht, Tae Min Kim, David J. Straus, Andrea Gallamini, Keenan Fenton, Ashish Gautam, Sergiy Alekseev, Gerald Engley, Anas Younes, Joseph M. Connors, Graham P. Collins, Árpád Illés, Andrew Grigg, Anna Sureda
Publikováno v:
Journal of Clinical Oncology. 36:7534-7534
7534Background: ECHELON-1 is a phase 3 study of BV plus doxorubicin, vinblastine, and dacarbazine (A+AVD) vs ABVD as frontline therapy in untreated advanced HL (NCT01712490). G-CSF primary prophyla...